[go: up one dir, main page]

Yeom et al., 1989 - Google Patents

Pharmacokinetics and bioavailability of carbovir, a carbocyclic nucleoside active against human immunodeficiency virus, in rats

Yeom et al., 1989

View PDF
Document ID
12057983267358939786
Author
Yeom Y
Remmel R
Huang S
Hua M
Vince R
Zimmerman C
Publication year
Publication venue
Antimicrobial agents and chemotherapy

External Links

Snippet

Carbovir is a novel carbocyclic nucleoside which has been shown to have potent in vitro activity against human immunodeficiency virus, the causative agent of acquired immunodeficiency syndrome. Sprague-Dawley male rats were used to investigate the …
Continue reading at journals.asm.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48169—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00—Drug, bio-affecting and body treating compositions
    • Y10S514/893—Liver disorder

Similar Documents

Publication Publication Date Title
Arndt et al. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system
Vassal et al. Pharmacokinetics of high-dose busulfan in children
Yeom et al. Pharmacokinetics and bioavailability of carbovir, a carbocyclic nucleoside active against human immunodeficiency virus, in rats
de Miranda et al. Species differences in the disposition of acyclovir
Pourbaix et al. Absolute bioavailability of amiodarone in normal subjects
Laskin et al. Azidothymidine steady-state pharmacokinetics in patients with AIDS and AIDS-related complex
Kim et al. Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects
KR19980703423A (en) Azathioprine compositions for colon administration
Sandström et al. Metoprolol excretion into breast milk
Cload A review of the pharmacokinetics of zidovudine in man
Han et al. Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first‐pass effect in rats
Huang et al. The bioavailability and nonlinear clearance of (–)-carbovir in the rat
Park et al. Mechanism and site dependency of intestinal mucosal transport and metabolism of thymidine analogues
Bach et al. The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.
Jawad et al. Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients.
KOJIMA et al. Pharmacokinetics of spironolactone and potassium canrenoate in humans
US4178376A (en) Method for inducing rapid therapeutically effective antimalarial levels of certain selected conventional antimalarials
SUMI et al. Pharmacokinetic study of carbamazepine and its epoxide metabolite in humans
Kurowski et al. Transsynovial distribution and protein binding of pirazolac in patients with rheumatoid arthritis
Joyce et al. The pharmacokinetics of albumin conjugates of D-penicillamine in humans.
Zimmerman et al. Pharmacokinetic evaluation of (-)-6-aminocarbovir as a prodrug for (-)-carbovir in rats.
Howrie et al. Disposition of moracizine (ethmozine) in healthy subjects after oral administration of radiolabelled drug
Brouwer et al. The pharmacokinetics of (-)-carbovir in rats. Evidence for nonlinear elimination.
Silke et al. Pharmacokinetic and pharmacodynamic studies with prazosin in chronic heart failure
Kremer et al. Zidovudine Phamacokinetics in Five HIV Seronegative Patients Undergoing Continuous Ambulatory Peritoneal Dialysis